Uplizna Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The uplizna market research report is one of a series of new reports that provides uplizna market statistics, including uplizna industry global market size, regional shares, competitors with a uplizna market share, detailed uplizna market segments, market trends and opportunities, and any further data you may need to thrive in the uplizna industry. This uplizna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing prevalence of neuromyelitis optica spectrum disorder, rising incidence of treatment-resistant NMOSD cases, rising support from healthcare policies, increasing global funding for rare disease research initiatives, growing number of clinical trials, and growing demand for biologics. Major trends in the forecast period include technological advancements, integration of AI, machine learning, digital health platforms, and combination therapies.

The growing prevalence of multiple sclerosis is expected to drive the expansion of the uplizna market in the coming years. Multiple sclerosis (MS) is a chronic autoimmune condition that affects the central nervous system, causing a variety of neurological symptoms. Factors contributing to the rising incidence of MS include better diagnostic tools, increased awareness, an aging population, and genetic factors. Uplizna helps patients by targeting and depleting B cells, reducing inflammation, and preventing disease progression. This makes it a promising treatment for managing this chronic condition. For example, in July 2024, the National Health Service (NHS) England reported that more than 150,000 people in the UK are affected by multiple sclerosis, with over 120,000 in England alone, and the disease is more common in women. As the prevalence of MS increases, so does the demand for uplizna, driving the market forward.

A significant trend in the uplizna market is the focus on obtaining regulatory approvals to expand its use for rare autoimmune diseases, increasing accessibility for patients. Regulatory approval ensures that a product meets safety, efficacy, and compliance standards, enabling it to reach the market and gain consumer trust. For instance, in June 2022, Horizon Therapeutics filed for regulatory approval of Uplizna (inebilizumab) with Brazil's National Health Surveillance Agency (ANVISA) for treating adult patients with anti-aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare and severe neurological disease. This move is part of Horizon’s broader strategy to make Uplizna available to NMOSD patients around the world. The drug has already received approvals in the U.S., Japan, and Europe, with clinical trials showing that it significantly reduces the risk of NMOSD attacks. If approved in Brazil, it could provide a new treatment option for the estimated 10,000 people living with NMOSD in the country.

In June 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics for an undisclosed amount. This acquisition allowed Amgen to expand its portfolio and strengthen its capabilities in the biotechnology sector. By combining their resources, both companies aim to drive innovation and growth in healthcare, enhancing research and development efforts and broadening their product offerings. Horizon Therapeutics is known for its work on Uplizna and specializes in developing treatments for autoimmune diseases.

The key company operating in the uplizna market is Amgen Inc

North America was the largest region in the uplizna market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in uplizna report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the uplizna market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Uplizna (also known as ozanimod) is an oral medication approved for treating relapsing forms of multiple sclerosis (MS). It acts as a sphingosine 1-phosphate receptor modulator, reducing the migration of immune cells to the central nervous system, which helps manage MS symptoms. Uplizna has been shown to decrease the frequency of relapses and slow the progression of disability in patients with relapsing MS, thereby improving overall quality of life.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for uplizna are neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). Neuromyelitis optica spectrum disorder is a rare autoimmune condition that affects the central nervous system, causing inflammation and damage to the optic nerves and spinal cord. Uplizna is distributed through various channels, including hospitals, clinics, retail, and specialty pharmacies. It is used by a range of end-users, including adult and geriatric patients.

The uplizna market consists of sales of injectable solution (IV Infusion), pre-filled syringe, and vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.